A revenue cycle director I spoke with recently described her evaluation process for an AI medical coding solution as “comparing five different vendors’ definitions of the word accurate.” She wasn’t exaggerating. Every vendor in this space quotes an accuracy figure in the high 90s, and almost none of them define the term the same way. One measures the exact code match against a certified coder’s output. Another measure is the first-pass acceptance rate before human review. A third quotes specificity-adjusted accuracy, which can look ten to twenty percentage points better than exact match on the same underlying performance. None of these numbers is dishonest on its own. The problem is that they aren’t comparable to each other, and most procurement processes never ask which one they’re looking at.
That gap between vendor marketing and reproducible evidence is where most bad AI medical coding decisions get made. Here’s a more structured way to evaluate what you’re actually being sold.
Start With How Accuracy Is Defined, Not the Number Itself
Before comparing any two vendors, ask each one to define their accuracy metric in plain terms and show you the calculation. Exact code match, specificity-adjusted accuracy, and first-pass acceptance rate are not interchangeable, and a platform can post a strong number on one metric while performing considerably worse on another. The industry has generally converged on a 95% coding accuracy benchmark as the practical standard providers should be measuring against, which gives you a useful anchor point once you know which definition a vendor is actually reporting.
Insist on a Statistically Valid Validation Sample, Not a Curated One
A handful of impressive demo encounters tells you almost nothing about production performance. Legitimate coding accuracy audits typically review a statistically valid sample in the range of 100 to 200 charts, pulled across your actual payer mix and specialty distribution, not a set the vendor selected in advance. Ask the vendor to run this kind of validation against your own recent encounters before you sign anything, with the sample composition agreed on jointly rather than chosen by the party being evaluated. If a vendor resists a validation structured this way, that reluctance is itself useful information.
Confirm Every Code Traces Back to Supporting Documentation
This requirement moved from best practice to compliance necessity in 2026. HHS-OIG issued its first Medicare Advantage compliance guidance in nearly three decades earlier this year, and it specifically raised concerns about AI-generated coding prompts adding diagnoses that the underlying medical record doesn’t clearly support. Separately, CMS has been tightening the audit sample methodology used in RADV reviews, which means the statistical bar for defending a coded diagnosis during an audit keeps rising. Ask any AI medical coding solution to demonstrate, on a live chart, exactly how a given code maps back to the sentence, value, or documented finding that justifies it. If that trace isn’t visible during the sales process, it won’t be available during an actual audit either.
Ask for Specialty-Segmented Performance, Not a Blended Average
A platform advertising strong accuracy across “all specialties” is almost always describing a blended average that favors high-volume, low-complexity encounters, such as routine office visits and common diagnoses. Performance on complex inpatient cases, oncology staging, or lower-volume specialties often sits meaningfully below that headline number. Request accuracy broken out by your organization’s actual specialty mix rather than an aggregate figure that hides where the platform is weakest, particularly if your claim volume leans toward the more complex end of that range.
Run the ROI Math With Denial Prevention Included, Not Just License Cost
A subscription price on its own is an incomplete comparison. Claim denial rates have continued climbing past 10 percent industrywide in 2026 as payer scrutiny intensifies, and roughly 42% of those denials trace back to fixable coding errors rather than clinical or payer disputes. Coding mistakes alone are estimated to cost the US healthcare system upward of $125 billion a year. A platform that costs more upfront but meaningfully reduces denial-driven rework can pay for itself well inside the first year. The math changes considerably once that offset is included, which is why comparing vendors on sticker price alone tends to produce the wrong decision.
Understand Whether an AI Medical Coding Solution Actually Fits Your Organization
Not every organization is well served by an off-the-shelf platform, and not every organization has the volume, talent, or timeline tolerance to build one internally either. The right platform needs to be evaluated against your specific documentation style, specialty concentration, and existing revenue cycle workflows, not against a generic feature checklist that looks similar across vendors. Organizations that skip this step tend to end up with a platform that scores well in a demo and underperforms once it meets their actual charting patterns.
The Evaluation That Actually Predicts Performance
None of the criteria above require deep technical expertise to apply. They require slowing the process down long enough to ask what a vendor’s accuracy number actually means, insisting on validation against your own data instead of theirs, and confirming that every code can be traced back to real documentation before an auditor asks the same question. Organizations that build their evaluation process around these questions consistently end up with platforms that hold up in production. The ones that don’t tend to find out the difference during their first denial spike or their first compliance review, which is a considerably more expensive place to learn it.
That evaluation should also include an honest look at whether buying is even the right starting question. Some organizations have genuine reasons, proprietary revenue cycle strategies, unusual documentation formats, or strict data ownership requirements to consider building a coding model internally instead of licensing one. Running that comparison through a structured build vs. buy AI medical coding framework before committing to either path produces a more defensible decision than choosing based on which option feels less risky in the moment.